PL3566696T3 - Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu - Google Patents
Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiuInfo
- Publication number
- PL3566696T3 PL3566696T3 PL19176691T PL19176691T PL3566696T3 PL 3566696 T3 PL3566696 T3 PL 3566696T3 PL 19176691 T PL19176691 T PL 19176691T PL 19176691 T PL19176691 T PL 19176691T PL 3566696 T3 PL3566696 T3 PL 3566696T3
- Authority
- PL
- Poland
- Prior art keywords
- sustained release
- release microsphere
- microsphere composition
- risperidone sustained
- risperidone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110102840 | 2011-04-25 | ||
| PCT/CN2012/000473 WO2012146052A1 (en) | 2011-04-25 | 2012-04-10 | Risperidone sustained release microsphere composition |
| EP16179390.6A EP3199146B1 (en) | 2011-04-25 | 2012-04-10 | Risperidone sustained release microsphere composition |
| EP19176691.4A EP3566696B1 (en) | 2011-04-25 | 2012-04-10 | Risperidone sustained release microsphere composition |
| EP12777430.5A EP2701687B1 (en) | 2011-04-25 | 2012-04-10 | Risperidone sustained release microsphere composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3566696T3 true PL3566696T3 (pl) | 2021-04-19 |
Family
ID=47071591
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16179390T PL3199146T3 (pl) | 2011-04-25 | 2012-04-10 | Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu |
| PL20199849.9T PL3772354T3 (pl) | 2011-04-25 | 2012-04-10 | Kompozycja mikrosfer rysperydonu o przedłużonym uwalnianiu |
| PL12777430T PL2701687T3 (pl) | 2011-04-25 | 2012-04-10 | Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu |
| PL19176691T PL3566696T3 (pl) | 2011-04-25 | 2012-04-10 | Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16179390T PL3199146T3 (pl) | 2011-04-25 | 2012-04-10 | Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu |
| PL20199849.9T PL3772354T3 (pl) | 2011-04-25 | 2012-04-10 | Kompozycja mikrosfer rysperydonu o przedłużonym uwalnianiu |
| PL12777430T PL2701687T3 (pl) | 2011-04-25 | 2012-04-10 | Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9446135B2 (pl) |
| EP (4) | EP3199146B1 (pl) |
| JP (2) | JP5728128B2 (pl) |
| KR (2) | KR101539313B1 (pl) |
| CN (2) | CN103338752B (pl) |
| AU (1) | AU2012248038B2 (pl) |
| BR (1) | BR112013027235B1 (pl) |
| CA (1) | CA2832663C (pl) |
| ES (4) | ES2968917T3 (pl) |
| HU (4) | HUE066287T2 (pl) |
| PL (4) | PL3199146T3 (pl) |
| PT (3) | PT3199146T (pl) |
| RU (1) | RU2586306C2 (pl) |
| WO (1) | WO2012146052A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199146B1 (en) | 2011-04-25 | 2019-07-17 | Shan Dong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
| CN103990114B (zh) * | 2014-05-06 | 2016-05-18 | 浙江圣兆药物科技股份有限公司 | 一种艾塞那肽缓释微球组合物 |
| JP2016102093A (ja) * | 2014-11-28 | 2016-06-02 | ニプロ株式会社 | 塩基性の求核化合物を含有するマイクロカプセルの製造方法 |
| EP3348268A4 (en) * | 2015-09-07 | 2019-04-10 | Nipro Corporation | RISPERIDO-CONTAINING MICRO-CAPSULES, METHOD FOR THE MANUFACTURE THEREOF, AND RELEASE CONTROL PROCEDURES |
| CN105560192A (zh) * | 2016-01-07 | 2016-05-11 | 万全万特制药江苏有限公司 | 一种棕榈酸帕利哌酮长效微球注射液的制备方法 |
| WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| CN106390102A (zh) * | 2016-11-30 | 2017-02-15 | 郑州仁宏医药科技有限公司 | 一种治疗精神分裂症的西药组合物 |
| CN116270486A (zh) * | 2017-01-24 | 2023-06-23 | 广州帝奇医药技术有限公司 | 水难溶或微溶性药物缓释组合物及其制备方法 |
| CN106822043A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 利培酮缓释组合物及其制备方法 |
| CN106822042A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 一种利培酮缓释组合物及其制备方法 |
| CN106727589A (zh) * | 2017-01-24 | 2017-05-31 | 广州帝奇医药技术有限公司 | 帕利哌酮及其衍生物的缓释组合物与该缓释组合物的制备方法 |
| CN106963746A (zh) * | 2017-03-17 | 2017-07-21 | 广州帝奇医药技术有限公司 | 一种水难溶/微溶性药物缓释组合物 |
| CN107349175A (zh) * | 2017-06-06 | 2017-11-17 | 浙江理工大学 | 一种负载脂肪褐变剂的微针贴片及其制备方法 |
| CN107049985B (zh) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | 一种抗帕金森病药物的长效缓释制剂及其制备方法 |
| CN107213136B (zh) * | 2017-06-07 | 2021-06-01 | 广州帝奇医药技术有限公司 | 一种长效缓释药物制剂及其制备方法 |
| CN107412188A (zh) * | 2017-09-06 | 2017-12-01 | 广州中医药大学 | 阿塞那平微球及其制备方法和其注射剂 |
| CN108498456B (zh) * | 2018-05-16 | 2021-01-01 | 丽珠医药集团股份有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
| CN108635339B (zh) * | 2018-08-06 | 2021-07-06 | 深圳市泛谷药业股份有限公司 | 一种利培酮植入剂及其制备方法 |
| GR1009870B (el) * | 2019-07-09 | 2020-11-12 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει ενα ατυπο αντιψυχωσικο φαρμακο και μεθοδος παρασκευης αυτου |
| JP7550474B2 (ja) * | 2019-12-31 | 2024-09-13 | 広州帝奇医薬技術有限公司 | 第３級アミン医薬組成物の工業化バッチ調製方法 |
| JP7805659B2 (ja) * | 2021-06-23 | 2026-01-26 | ペプトロン インコーポレイテッド | セマグルチド又はその薬学的に許容可能な塩を含む徐放性製剤組成物 |
| CN115006354A (zh) * | 2022-06-16 | 2022-09-06 | 北京阳光诺和药物研究股份有限公司 | 一种利培酮-共混plga缓释微球及其制备方法 |
| EP4593882A1 (en) * | 2022-09-26 | 2025-08-06 | The Methodist Hospital | Microparticle formulations for intravenous therapy and methods for their manufacture and use |
| CN118831056A (zh) * | 2023-04-11 | 2024-10-25 | 珠海市华海康医药科技有限责任公司 | 一种注射用非奈利酮缓释微球及其制备方法 |
| CN119606887A (zh) * | 2023-11-09 | 2025-03-14 | 武汉人福创新药物研发中心有限公司 | 一种药物缓释微球组合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| ATE188375T1 (de) * | 1992-11-17 | 2000-01-15 | Yoshitomi Pharmaceutical | Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung |
| ATE288270T1 (de) | 1993-11-19 | 2005-02-15 | Janssen Pharmaceutica Nv | Mikroverkapselte 1,2-benzazole |
| US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
| MXPA05004927A (es) * | 2002-11-06 | 2005-09-08 | Alza Corp | Formulaciones de deposito de liberacion controlada. |
| EP1615924A1 (en) * | 2003-04-22 | 2006-01-18 | Synthon B.V. | Water soluble salts of risperidone |
| DK1742616T3 (en) * | 2004-04-30 | 2015-01-12 | Abraxis Bioscience Llc | The microsphere-discharge-system for the prolonged delivery and methods of making and using the same |
| DE602005010812D1 (de) * | 2004-11-22 | 2008-12-18 | Hisamitsu Pharmaceutical Co | Transdermales Pflaster enthaltend einen schmelzpunktsenkenden Hilfsstoff |
| RU2464972C2 (ru) | 2005-12-22 | 2012-10-27 | Новартис Аг | Композиции с замедленным высвобождением, включающие октреотид и два или более сополимера полилактида и гликолида |
| CN101292960B (zh) * | 2006-04-29 | 2011-02-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 含利培酮的缓释微球及其制备方法 |
| PE20090387A1 (es) | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| JP5222550B2 (ja) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
| CN101653422B (zh) | 2008-08-20 | 2013-03-20 | 山东绿叶制药有限公司 | 利培酮缓释微球、其制备方法和用途 |
| CN101584652B (zh) | 2009-06-19 | 2012-06-20 | 上海医药集团股份有限公司 | 利培酮缓释凝胶注射剂及其制备方法 |
| UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| EP3199146B1 (en) | 2011-04-25 | 2019-07-17 | Shan Dong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
-
2012
- 2012-04-10 EP EP16179390.6A patent/EP3199146B1/en active Active
- 2012-04-10 ES ES20199849T patent/ES2968917T3/es active Active
- 2012-04-10 KR KR1020137029953A patent/KR101539313B1/ko active Active
- 2012-04-10 PL PL16179390T patent/PL3199146T3/pl unknown
- 2012-04-10 BR BR112013027235-0A patent/BR112013027235B1/pt active IP Right Grant
- 2012-04-10 EP EP12777430.5A patent/EP2701687B1/en active Active
- 2012-04-10 JP JP2014506723A patent/JP5728128B2/ja active Active
- 2012-04-10 PL PL20199849.9T patent/PL3772354T3/pl unknown
- 2012-04-10 PL PL12777430T patent/PL2701687T3/pl unknown
- 2012-04-10 WO PCT/CN2012/000473 patent/WO2012146052A1/en not_active Ceased
- 2012-04-10 PT PT161793906T patent/PT3199146T/pt unknown
- 2012-04-10 ES ES12777430.5T patent/ES2607497T3/es active Active
- 2012-04-10 PT PT127774305T patent/PT2701687T/pt unknown
- 2012-04-10 US US14/113,738 patent/US9446135B2/en active Active
- 2012-04-10 PL PL19176691T patent/PL3566696T3/pl unknown
- 2012-04-10 CA CA2832663A patent/CA2832663C/en active Active
- 2012-04-10 CN CN201280006994.7A patent/CN103338752B/zh active Active
- 2012-04-10 HU HUE20199849A patent/HUE066287T2/hu unknown
- 2012-04-10 ES ES19176691T patent/ES2855349T3/es active Active
- 2012-04-10 PT PT191766914T patent/PT3566696T/pt unknown
- 2012-04-10 AU AU2012248038A patent/AU2012248038B2/en active Active
- 2012-04-10 EP EP20199849.9A patent/EP3772354B1/en active Active
- 2012-04-10 KR KR1020157010621A patent/KR101932207B1/ko active Active
- 2012-04-10 HU HUE19176691A patent/HUE052864T2/hu unknown
- 2012-04-10 CN CN201410314847.7A patent/CN104127385B/zh active Active
- 2012-04-10 HU HUE16179390A patent/HUE046004T2/hu unknown
- 2012-04-10 HU HUE12777430A patent/HUE032310T2/hu unknown
- 2012-04-10 RU RU2013147949/15A patent/RU2586306C2/ru active
- 2012-04-10 EP EP19176691.4A patent/EP3566696B1/en active Active
- 2012-04-10 ES ES16179390T patent/ES2749864T3/es active Active
-
2015
- 2015-04-02 JP JP2015075711A patent/JP6072121B2/ja active Active
-
2016
- 2016-07-22 US US15/217,696 patent/US9532991B2/en active Active
- 2016-11-09 US US15/347,365 patent/US10098882B2/en active Active
-
2018
- 2018-09-27 US US16/144,614 patent/US10406161B2/en active Active
-
2019
- 2019-07-29 US US16/525,502 patent/US11110094B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2701687T (pt) | Composição de microesferas de libertação sustida de risperidona | |
| EP2683668A4 (en) | HOLLOW MICROSPHERES | |
| ZA201309653B (en) | Controlled release peptide formulations | |
| ZA201202474B (en) | Controlled release compositions | |
| ZA201306118B (en) | Lyophilized formulations | |
| GB201102237D0 (en) | Particle formulation | |
| PL2554168T3 (pl) | Kompozycja farmaceutyczna do kontrolowanego uwalniania | |
| ZA201306016B (en) | Bendamustine formulations | |
| EP2744496A4 (en) | FORMULATIONS WITH TAXED RELEASE | |
| ZA201308316B (en) | Sustained release paracetamol formulations | |
| GB201103942D0 (en) | Compositions | |
| SG11201404915SA (en) | Sustained release oral solid preparation | |
| GB201110278D0 (en) | Formulations | |
| HUP1100207A2 (en) | Modified release composition | |
| GB201016615D0 (en) | Drug release composition | |
| HK1190074A (en) | Sustained release paracetamol formulations | |
| GB201105410D0 (en) | Formulations | |
| GB201104049D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201102795D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201111578D0 (en) | Pharmeutical formulations |